West Virginia University Logo

Disease Site: Multiple Myeloma

11 protocol(s) meet the specified criteria

  • 029SSpecimen Collection for Analytical and/or Clinical Validation Studies of the Xpert® BCR-ABL Ultra Assay on the GeneXpert® Instrument Systems
  • 231Clinical Evaluation of the Xpert® BCR-ABL Ultra Assay on the GeneXpert® Instrument Systems
  • BMTCTN1302Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
  • CLBH589D2222A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different regimens of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents.
  • COG-AAML1031COG-AAML1031 - A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for patients with High Allelic Ratio FLT3/ITD
  • E1A11Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
  • INCB18424-271A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment if Steroid Refractory Acute Graft-Versus-Host Disease
  • MK-3475-013A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies
  • NSMM-5001A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
  • PCYC-1140-IMA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)
  • PRO140CD03GVHDA Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Allogeneic Stem-Cell Transplantation